Issue 7/2025
Tomov, T., Radeva, Y, Yanev, K., Popova, I., Gerganov, Y., Mateev, G., Drenovska, K.
Department of Dermatology and Venereology, Medical University – Sofia
Malignant melanoma (MM) is a malignant tumor originating from the melanocytic cell system that mainly affects the skin. MM is known for its fast evolution, spreading to other organs and poor prognosis if not detected and treated in early stages. New treatment options with cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) blockers that represent the group of medications called check-point inhibitors have proven in the last years to be the new standard of treatment with adjuvant immunotherapy increasing the surviving rate with no relapses. Their usage was related to series of side effects including skin reactions, mostly manifested as immunotoxicity reactions. We present a 67-year-old male who showed immunotoxicity rection presented by a persistant generalized maculo-papular skin rash during treatment with the PD-1 inhibitor pembrolizumab, the latter being withdrawn from the treatment plan.
Key words: malignant melanoma, late immune-related toxicity, immune check-point inhibitors
Address for correspondence:
Dr. Toma Tomov
Department of Dermatology and Venereology,
MU-Sofia,University Hospital „Aleksandrovska“ EAD
1, „St. Georgi Sofiyski“, Str.
1431, Sofia
e-mail: toma_tomov2015@abv.bg